Warren K Lewis Lecture, May 1, 2026
Hope through Rigorous Science, Neil Kumar, PhD '07, CEO & Founder, BridgeBio Pharma, Inc. MIT ChemE.
Co-Founder and Chief Executive Officer, BridgeBio Pharma, Inc.
Search every verified Neil Kumar interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Neil Kumar, co-founder and CEO of BridgeBio Pharma, discussed the company’s development of the drug acoramidis for ATTR cardiomyopathy, a condition he described as an example of precision medicine in cardiovascular disease. He explained that the drug aims to stabilize the transthyretin tetramer by mimicking a naturally occurring “rescue mutation” that hyper-stabilizes the protein, contrasting it with an existing stabilizer that he said was designed before the mutation’s action was known and is less effective. Kumar noted that a clinical trial for acoramidis met its primary endpoint with a p-value of less than 0.0001, though he acknowledged that trials are not typically designed to achieve statistical significance on mortality alone due to low event rates. Kumar also spoke about BridgeBio’s transition from a development-focused company to one with both development and commercial operations, citing the drug’s third-quarter revenue of $108 million. He expressed a hope to build a sustainable company by responsibly marketing the medicine and repeating that process with other assets. Reflecting on leadership, he said he had “overpersonalized” downturns in the company’s history, which made him a less effective leader, and advised building a strong network of mentors and advisers while focusing on patient impact rather than daily stock movements.
Hope through Rigorous Science, Neil Kumar, PhD '07, CEO & Founder, BridgeBio Pharma, Inc. MIT ChemE.
BridgeBio Pharma Q4 2025 Earnings Conference Call. If you find our work useful, please support us by purchasing a Super Thanks— it truly helps us a lot. #earningscall #StockMarketNews #conferenceCall Earnings Call | Earnings Conference Call | Earnings concall | concall | quarterly results | Stock News | Full Year results | Fiscal Year results | investment news | stock latest news If you want us to remove your company's earnings call or any other conference call, please reach out to [email protected].
BridgeBio Pharma founder and CEO Neil Kumar reveals what drove him to help people with dwarfism on 'The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #health #medicine #biotech #pharma #children #family #genetics #research #innovation #treatment #rare #science #community #business Subscribe to Fox Business: https://bit.ly/2D9Cdse Watch more Fox Business Video: https://video.foxbusiness.com Watch Fox Business Network Live: http://www.foxnewsgo.com/ FOX Business Network (FBN) is a financial news channel delivering real-time infor…
Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.
Millions of people living with genetic diseases are still waiting for treatments. At BridgeBio, our mission is to put patients first and push the boundaries of science to meet those needs. Founder and CEO, Neil Kumar Ph.D., joined Deirdre Bolton at the Milken Institute Global Conference to highlight the urgency and opportunity in addressing rare and underserved conditions.
Presenting Neil Kumar, the CEO and visionary behind Bridge Biopharma, a cutting-edge pharmaceutical enterprise committed to pioneering treatments in genetic diseases. Join him as he shares insights into the company's journey, from discovery to commercialization, and its mission to serve rare disease patients globally. Don't miss this exclusive insights shared at IndoUS Rare Summit 2023. #bridge4rare #IndoUSRare #summit2023 #rarediseases #bridgingrare
What can Homer teach us about biotech? Has Big Science gotten too big? And what’s the future of treating Alzheimer’s disease? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Neil Kumar, CEO of BridgeBio, joins us to talk about how his small company came to develop what could be a big drug — and why classical Greek literature remains relevant. We also discuss the latest news in the life sciences, including the abrupt resignation of the celebrity scientist who led Stanford University and the implications of tornado damage at a Pfizer plant. More from STAT: B…
BridgeBio is building an outsider moat in drug development. Instead of relying on a core technology, the company has a private equity firm specializing in drug development and clinical programs embedded in it. BridgeBio’s advantages are the scale they can offer an individual drug program and the discipline to know which ones are worthwhile to underwrite. If the business can maintain its independence (an extremely rare event in biopharma), then overtime, each iterative program will improve the odds of success for the next one. BridgeBio has the potential to become a Danaher or Constellation typ…
Sign in to search the full transcript archive, filter by topic, and access every quote from Neil Kumar.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans